Insulet Stock Forecast, Price & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PODD stock has increased by 42.8% and is now trading at $245.83.
View which stocks have been most impacted by COVID-19.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Insulet.

Insulet will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Thursday, August, 6th. The medical instruments supplier reported $0.22 EPS for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.23. The medical instruments supplier earned $226.30 million during the quarter, compared to analysts' expectations of $212.41 million. Insulet had a return on equity of 10.96% and a net margin of 2.20%. Insulet's revenue for the quarter was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.02 earnings per share.
View Insulet's earnings history.

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $863.694-878.458 million, compared to the consensus revenue estimate of $849.76 million.

19 equities research analysts have issued twelve-month price objectives for Insulet's shares. Their forecasts range from $165.00 to $260.00. On average, they expect Insulet's share price to reach $223.88 in the next twelve months. This suggests that the stock has a possible downside of 8.9%.
View analysts' price targets for Insulet.

Insulet saw a decrease in short interest in September. As of September 30th, there was short interest totaling 2,440,000 shares, a decrease of 14.7% from the September 15th total of 2,860,000 shares. Based on an average daily trading volume, of 409,100 shares, the days-to-cover ratio is currently 6.0 days.
View Insulet's Short Interest.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Steris (STE) and Varian Medical Systems (VAR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), The Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.17%), Assenagon Asset Management S.A. (0.07%), Envestnet Asset Management Inc. (0.07%), State of Alaska Department of Revenue (0.04%), First Hawaiian Bank (0.01%) and Highland Capital Management LLC (0.01%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, HWG Holdings LP, Tributary Capital Management LLC, and First Hawaiian Bank. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet.

PODD stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of Alaska Department of Revenue, Candriam Luxembourg S.C.A., Scout Investments Inc., Harel Insurance Investments & Financial Services Ltd., IFM Investors Pty Ltd, Nachman Norwood & Parrott Inc, and IBM Retirement Fund.
View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $245.83.

Insulet has a market capitalization of $16.14 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]